Latest research on Erlotinib

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Latest findings

In our example, Erlotinib and Gefitinib were frequently lumped together in EGFR TYROSINE kinase inhibitors and Docetaxel and Pemetrexed were lumped together in monochemotherapy. [source, 2016]
After a preliminary screening study, we choose 3 target TKI drugs, including Erlotinib hydrochloride, Afatinib, and Sunitinib. [source, 2016]
In brief, Erlotinib is a drug used to treat non-small cell lung cancer and pancreatic cancer and is a reversible TKI, which acts on the epidermal growth factor receptor (EGFR) [18]. [source, 2016]
Afatinib (BIBW2992) and Erlotinib (OSI-420) were purchased from Selleck Chemicals (Houston, Texas, USA). [source, 2016]
The concentrations of Afatinib, Erlotinib, and Sunitinib were 10, 50, and 10 µM, respectively (Fig. 1). [source, 2016]
These results showed that Afatinib 10 µM completely inhibited the intracellular growth of T. gondii similar to the inhibitory effect of pyrimethamine 5 µM, whereas Erlotinib 50 µM and Sunitinib 10 µM did not inhibit the intracellular growth of the parasite. [source, 2016]
EGFR is a target for several anticancer therapeutics, such as TYROSINE kinase inhibitors Gefitinib and Erlotinib and monoclonal antibodies cetuximab and panitumumab (3). [source, 2016]
First-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI) including geiftinib and Erlotinib have been the standard first-line treatment for metastatic non-small-cell lung cancer (NSCLC) harboring activating EGFR mutation. [source, 2016]
Global and regional phase III randomized-controlled trials demonstrated that the median progression-free survival (PFS) after Gefitinib or Erlotinib ranged from 9 to 13 months with the longest PFS of 13.1 months seen in OPTIMAL study using Erlotinib [1–7]. [source, 2016]
The LUX-Lung1 study published in 2010 has demonstrated efficacy with improvement in progression-free survival (3.3 months) for those who had taken afatinib 50 mg daily compared to those who had placebo, after previous treatment with Gefitinib or Erlotinib for at least 12 weeks and at least one line of platinum-based chemotherapy [13]. [source, 2016]